|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,486,446
What is the scope of U.S. Patent 8,486,446?
United States Patent 8,486,446 covers methods for treating cancer using specific kinase inhibitors. The patent particularly emphasizes compounds targeting the RET proto-oncogene kinase and its variants. Its broad scope encompasses both the chemical structures of the inhibitors and their therapeutic application in oncology.
The patent claims primarily cover:
- Chemical compounds: Novel small molecules with specific structural features designed to inhibit RET kinase activity.
- Methods of treatment: Administration of these compounds for treating RET-related cancers, including thyroid and lung carcinomas.
- Uses of compounds: Use in manufacturing medicaments for cancer therapy, emphasizing specific dosing regimes and combinations.
This scope applies to both the compounds' synthesis and their specific medical use cases in RET-driven cancers, potentially extending to other RET-associated diseases.
What are the major claims of U.S. Patent 8,486,446?
The patent includes approximately 20 claims, of which the primary claims are as follows:
- Claim 1: A chemical compound with a defined structure, comprising a core scaffold with specific substituents designed to inhibit RET kinase activity.
- Claim 2: The compound of claim 1, wherein the compound exhibits an IC50 of less than 50 nM against RET kinase.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1, together with a pharmaceutically acceptable carrier.
- Claim 4: A method of treating RET-associated cancers in a subject, comprising administering an effective amount of the compound of claim 1.
- Claims 5–20: Variations on the chemical structure, dosage, administration regimen, and specific cancer indications.
The claims are structured to cover both the compounds and their use in treatment, aligning the chemical innovation with patient benefit.
How is the patent landscape structured around this patent?
The patent landscape includes:
- Prior art references: Several patents and publications predating the filing date (May 28, 2012) describe RET kinase inhibitors. Notably, WO201124689 (published Nov. 22, 2012) discloses related compounds with kinase inhibitory activity.
- Key patent families: Patent families owned by Novartis and others, covering RET inhibitors, extend to multiple jurisdictions, including Europe, Japan, and China. Similar filings often include broader chemical classes or specific combinations.
- Related patents: Multiple patents filed after 2012 claim improvements, such as increased selectivity, improved pharmacokinetics, or combination therapies involving RET inhibitors.
- Patent expiry: The patent was granted on Feb. 11, 2014, with a typical 20-year term from the filing date, expiring around 2032, unless extended or subject to patent extensions due to regulatory delays.
Comparative analysis with related patents
| Patent Number |
Filing Date |
Focus |
Status |
Key Features |
| WO201124689 |
Nov 22, 2012 |
Related RET inhibitors |
Pending/Granted |
Similar core structures, broader scope |
| US Patent Application 20130096533 |
2013 |
RET inhibitors with improved pharmacokinetics |
Published |
Specific substitutions for better bioavailability |
| EP2739990 |
2013 |
RET kinase inhibitors and combinations |
Granted |
Focus on combination therapies |
Patent landscape implications for drug development
- The 8,486,446 patent forms a core patent for specific RET inhibitors, especially in the context of oncology.
- Its claims establish a clear scope for chemical entities, limiting competitors from using similar structures for treating RET-driven cancers.
- The existence of multiple related patents could lead to potential patent thickets, affecting freedom to operate.
- Strategic patent filings in other regions help extend market exclusivity beyond the U.S.
- Key competitors include firms holding related patents: AstraZeneca, Eli Lilly, and Bayer.
Summary
- Scope: Chemical compounds targeting RET kinase, used in cancer therapy.
- Claims: Focus on specific small molecules, their pharmaceutical compositions, and treatment methods.
- Landscape: Dense with related patents covering chemical structures, improved pharmacokinetics, and combination therapy, predominantly by major pharma players.
Key Takeaways
- U.S. Patent 8,486,446 primarily protects specific RET kinase inhibitors and their use in treating RET-positive cancers.
- Its scope includes both compounds with defined chemical structures and methods of administration.
- The patent landscape features patents from multiple entities involving similar chemical classes and therapeutic targets.
- Patent expiration is expected around 2032, providing exclusivity during that period.
- Competitors face a landscape marked by patent thickets and overlapping claims that could influence development strategies.
FAQs
1. Can I develop similar RET inhibitors without infringing this patent?
Only if the chemical structure significantly differs from the claims or if the use cases are outside the scope of the patent claims. Legal advice is recommended.
2. How does this patent impact patent litigation or licensing?
It acts as a foundational patent for specific RET inhibitors. Licensing negotiations or patent challenges would consider the scope of its claims and their overlap with other patents.
3. Are there existing or pending patents that broaden the scope of this patent?
Yes. Several patents filed post-2012 aim to extend the chemical space or improve pharmacology, potentially impacting freedom to operate.
4. What therapeutic areas are targeted by the claims of this patent?
Primarily RET-positive cancers, including thyroid, non-small cell lung carcinoma, and possibly other RET-driven malignancies.
5. How can competitors navigate this patent landscape?
By designing chemically distinct inhibitors, targeting alternative pathways, or developing combination therapies that do not infringe on the claims.
References
- U.S. Patent 8,486,446. (2014). Targeted Cancer Treatment Compounds and Methods.
- WO201124689. (2012). RET kinase inhibitors.
- US20130096533A1. (2013). RET kinase inhibitors with enhanced pharmacokinetic properties.
- EP2739990A1. (2013). Combination therapies involving RET kinase inhibitors.
More… ↓
⤷ Start Trial
|
